161 related articles for article (PubMed ID: 18331669)
1. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
Armstrong EP; Malone DC; Erder MH
Curr Med Res Opin; 2008 Apr; 24(4):1115-21. PubMed ID: 18331669
[TBL] [Abstract][Full Text] [Related]
2. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
Armstrong EP; Skrepnek GH; Haim Erder M
Curr Med Res Opin; 2007 Feb; 23(2):251-8. PubMed ID: 17288678
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
Annemans L; Brignone M; Druais S; De Pauw A; Gauthier A; Demyttenaere K
Pharmacoeconomics; 2014 May; 32(5):479-93. PubMed ID: 24554474
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
Demyttenaere K; Hemels ME; Hudry J; Annemans L
Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
Choy E; Richards S; Bowrin K; Watson P; Lloyd A; Sadosky A; Zlateva G
Curr Med Res Opin; 2010 Apr; 26(4):965-75. PubMed ID: 20178405
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
Fantino B; Moore N; Verdoux H; Auray JP
Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
Dolder C; Nelson M; Stump A
Drugs Aging; 2010 Aug; 27(8):625-40. PubMed ID: 20658791
[TBL] [Abstract][Full Text] [Related]
12. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
Wade AG; Toumi I; Hemels ME
Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
14. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
[TBL] [Abstract][Full Text] [Related]
15. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Wielage R; Bansal M; Wilson K; Klein R; Happich M
Spine (Phila Pa 1976); 2013 May; 38(11):936-46. PubMed ID: 23250234
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
Lam RW; Andersen HF; Wade AG
Int Clin Psychopharmacol; 2008 Jul; 23(4):181-7. PubMed ID: 18545055
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.
Wade A; Gembert K; Florea I
Curr Med Res Opin; 2007 Jul; 23(7):1605-14. PubMed ID: 17559755
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
Nordström G; Danchenko N; Despiegel N; Marteau F
Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
[TBL] [Abstract][Full Text] [Related]
20. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
